Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, Wuhan, 430022, China.
Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 430022, China.
J Hematol Oncol. 2024 May 6;17(1):29. doi: 10.1186/s13045-024-01550-9.
Currently, many off-the-shelf chimeric antigen receptor (CAR)-T cell products are under investigation for the treatment of relapsed or refractory (R/R) B-cell neoplasms. Compared with autologous CAR-T cell therapy, off-the-shelf universal CAR-T cell therapies have many potential benefits, such as immediate accessibility for patients, stable quality due to industrialized manufacturing and additional infusions of CAR-T cells with different targets. However, critical challenges, including graft-versus-host disease and CAR-T cell elimination by the host immune system, still require extensive research. The most common technological approaches involve modifying healthy donor T cells via gene editing technology and altering different types of T cells. This article summarizes some of the latest data from preclinical and clinical studies of off-the-shelf CAR-T cell therapies in the treatment of R/R B-cell malignancies from the 2023 ASH Annual Meeting (ASH 2023).
目前，许多现成的嵌合抗原受体（CAR）-T 细胞产品正在被研究用于治疗复发或难治性（R/R）B 细胞肿瘤。与自体 CAR-T 细胞治疗相比，现成的通用 CAR-T 细胞治疗具有许多潜在的好处，例如患者可以立即获得治疗，由于工业化制造和输注不同靶点的 CAR-T 细胞，质量稳定。然而，仍需要广泛的研究来解决一些关键挑战，包括移植物抗宿主病和宿主免疫系统对 CAR-T 细胞的清除。最常见的技术方法包括通过基因编辑技术修饰健康供体 T 细胞和改变不同类型的 T 细胞。本文总结了 2023 年美国血液学会（ASH）年会（ASH 2023）上关于现成的 CAR-T 细胞治疗 R/R B 细胞恶性肿瘤的一些最新的临床前和临床研究数据。
